Reference priceRUB ₽57,750.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Minjuvi |
|---|---|
| Manufacturer | INCYTE BIOSCIENCES IBERIA S.L. |
| Prescription required | Yes |
Minjuvi 200mg polvo 1vial x 1(tafasitamab)
tafasitamab
Description
Minjuvi 200mg polvo 1vial x 1(tafasitamab) is a medicine catalog record in the MediPriceHub database. Active ingredient: tafasitamab. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: INCYTE BIOSCIENCES IBERIA S.L.. Therapeutic category: Medicine Library > Oncology Medicines > Lymphoma medication. Pack information: 200 1. Origin country or market: Spain. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
MONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).How to Use
Use tafasitamab under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: tafasitamab. Pack size: 200 1. Pack unit: bottle. Manufacturer: INCYTE BIOSCIENCES IBERIA S.L.. Origin country: Spain. Source category: Medicine Library > Oncology Medicines > Lymphoma medication. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Эта информация носит справочный характер. Перед применением лекарства проконсультируйтесь с медицинским специалистом.